Page 61 - CJO_F17_GLAUCOMA_SUPPLEMENT

MANAGING OPEN ANGLE GLAUCOMA

Appendix 2 – Topical Glaucoma Medication Review

Glaucoma
Prostanoids/Prostamides
Drug Year Concentration Brand Name Dosing Bottle Size Preservative
latanoprost 1996 0.005% XALATAN QD, hs 2.5 mL BAK
(ester) (and generics)
BAK
travoprost (ester) 2001 0.004% (generics only) QD (hs) 2.5 mL SOFZIA
(boric acid,
travoprost (ester) 0.004% TRAVATAN Z (and generics) QD (hs) 2.5 mL propylene glycol,
sorbitol, zinc
chloride)
bimatoprost
(amide) 2002 0.03% LUMIGAN QD (hs) 3 mL 0.005% BAK
(and generics)
bimatoprost 2012 0.01% LUMIGAN RC QD (hs) 3 mL 0.02% BAK
(amide)
ZIOPTAN (US) or
tafluprost (ester) 2012 0.0015% QD (hs) 10 x 0.3mL/vial PF
SAFLUTAN (elsewhere)
Beta-Adrenergic Blocking Agents (non-selective; ß1 & ß2)
0.25 TIMOPTIC (and generics) QD 5, 10 mL BAK
0.5% (am)
1978 +
timolol 0.25% Timoptic XE (q.d. dosing) QD 5mL (GEL);
0.5% (am) OCUDOSE PLUS
QD
levobunolol HCl 0.25 0.5% BETAGAN (and generics) 5, 10, 15 mL BAK
(am)
Beta-Adrenoceptorc Blocking Agents (cardioselective; ß1)
betaxolol 1998 0.25% Betoptic S BID Susp 5, 10 mL BAK
betaxolol 0.5% (generic only) BID ? BAK

Adrenomimetics Alpha2-selective Adrenergic Agonists
(note: non-selective epinephrine, dipivefrin not used)
dipivefrin 1992 0.1 % Propine (and generics) BID 10, 15 mL BAK
0.5% 10, 15 mL BAK
apraclonidine 1994 Iopidine 0.5% BID
1.0% ampules (PF) PF
0.15% ALPHAGAN-P (Canada) TID (or Purite
brimonidine 1996 + BID if 5, 10, 15 mL
0.2%, 0.15% (generics) adding) BAK
Carbonic Anhydrase Inhibitors – Topical
TID (or
dorzolamide 1994 2% TRUSOPT BID if 5 mL BAK
adding)
TID (or
brinzolamide 2000 1% AZOPT BID if Susp – 2.5, 5, 10, BAK
adding 15 mL

CANADIAN JOURNAL of OPTOMETRY | REVUE CANADIENNE D’OPTOMÉTRIE VOL. 79 SUPPLEMENT 1, 2017 61